Stay updated on Upifitamab Rilsodotin+Carboplatin in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Upifitamab Rilsodotin+Carboplatin in Ovarian Cancer Clinical Trial page.

Latest updates to the Upifitamab Rilsodotin+Carboplatin in Ovarian Cancer Clinical Trial page
- Check2 days agoChange DetectedAdded a Locations section specifying Michigan as the study site. Removed the HHS Vulnerability Disclosure link and updated the page revision from v3.3.2 to v3.3.3.SummaryDifference0.2%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2, with no changes to study details or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check37 days agoChange DetectedThe government funding notice at the bottom of the page has been removed; the rest of the study details, eligibility criteria, and contact information remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check52 days agoChange DetectedThe study details page shows no substantive changes between screenshots, with only minor layout variations observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check80 days agoChange DetectedMajor update: adds a government funding/operating status notice and updates version to v3.2.0, replacing the previous v3.1.0.SummaryDifference3%

- Check87 days agoChange DetectedThe page now indicates revision v3.1.0 and no longer lists v3.0.2.SummaryDifference0.1%

Stay in the know with updates to Upifitamab Rilsodotin+Carboplatin in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Upifitamab Rilsodotin+Carboplatin in Ovarian Cancer Clinical Trial page.